Clinical Scorecard: Fifteen Additional Medications Included in Medicare Price Negotiation Process
At a Glance
Category
Detail
Condition
Various chronic diseases including cancer, autoimmune diseases, HIV, asthma, COPD, cardiovascular diseases, schizophrenia, and migraine
Key Mechanisms
Medicare price negotiation for selected drugs including physician-administered Part B drugs and retail Part D drugs
Target Population
Medicare beneficiaries including those in traditional Medicare and Medicare Advantage plans
Care Setting
Physician offices and retail pharmacy settings
Key Highlights
First inclusion of physician-administered drugs (Part B) in Medicare price negotiation starting 2028.
Fifteen drugs selected cover a range of conditions such as cancer, HIV, autoimmune diseases, and chronic conditions.
Protected-class drugs like certain cancer and HIV therapies may yield significant Medicare savings due to negotiation.
Guideline-Based Recommendations
Diagnosis
Use standard clinical criteria to diagnose conditions such as HIV, cancer types, autoimmune diseases, asthma, COPD, cardiovascular diseases, schizophrenia, and migraines.
Management
Incorporate negotiated drugs into treatment regimens as appropriate for the indicated conditions.
Consider both physician-administered and self-administered formulations depending on patient needs and drug availability.
Monitoring & Follow-up
Monitor therapeutic response and adverse effects according to standard practice for each drug and condition.
Track utilization data especially for Part B drugs in Medicare Advantage plans to inform ongoing management.
Risks
Be aware of potential access or coverage variations between traditional Medicare and Medicare Advantage plans.
Consider individual patient factors and comorbidities when selecting therapies from the negotiated drug list.
Patient & Prescribing Data
Medicare beneficiaries with chronic and complex conditions requiring specialty and maintenance therapies
Negotiated pricing aims to reduce costs for high-expense drugs, potentially improving affordability and access for patients.
Clinical Best Practices
Review updated Medicare drug lists annually to incorporate newly negotiated medications into formularies.
Coordinate care between physicians and pharmacists to optimize use of physician-administered and retail drugs.
Educate patients on drug indications, administration routes, and potential cost savings under Medicare negotiation.
